Details :
Afinitor Disperz (everolimus) is an mTOR inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of tuberous sclerosis complex.
Details :
Everolimus is the generic name for the trade name drug Afinitor. Breckenridge has launched 10mg strength of Everolimus Tablets used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumo...
Details :
Zortress-Generic (everolimus) inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. It is indicated for the prophylaxis of organ rejection in adult patients.
Details :
Breckenridge plans to launch Everolimus Tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021 in a blister card packaging configuration.
Details :
Torpenz (everolimus) inhibits antigenic and interleukin (IL-2/15) stimulated activation and proliferation of T and B lymphocytes. It is indicated for Tuberous Sclerosis Complex.
Details :
The FDA approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System to keep arteries open, delivering Everolimus to support healing in patients with chronic limb-threatening ischemia.
Details :
Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Details :
The net financing will support the development of ITM’s broad Targeted Radionuclide Therapies oncology pipeline and enhance phase III clinical development for its lead pipeline candidate, ITM-11 (n.c.a. 177Lu-edotreotide) in gastroenteropancreatic neur...
Product Name : ITM-11
Product Type : Peptide
Upfront Cash : Undisclosed
June 05, 2023
Lead Product(s) :
n.c.a. 177Lu-Edotreotide,Everolimus
Details :
Everolimus tablets, a generic version of Afinitor® have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet used to treat certain types of cancers and tumours.
Details :
Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.
Reset All
